{"id":"W2099562503","doi":"10.1200/jco.2009.22.1077","title":"Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":152,"is_retracted":false,"has_abstract":true,"ca_institutions":"Baker Hughes (Canada); Saskatchewan Cancer Agency; McMaster University; BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Amgen; Queen's University; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Epirubicin; Cyclophosphamide; Breast cancer; Internal medicine; Febrile neutropenia; Hazard ratio; Fluorouracil; Chemotherapy; Doxorubicin; Gastroenterology; Oncology; Cancer; Neutropenia; Confidence interval","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00307561,0.00105172,0.004486278,0.000366934,0.0003017681,0.00006977545,0.000321469,0.001296623,0.0003248497],"category_scores_gemma":[0.003136309,0.0008105802,0.000570207,0.0007145883,0.001130374,0.0005897381,0.0001914142,0.002713448,0.00001326085],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001166521,"about_ca_system_score_gemma":0.00160311,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00518928,"about_ca_topic_score_gemma":0.002558459,"domain_scores_codex":[0.9913369,0.00131796,0.003943424,0.001297676,0.000828895,0.001275133],"domain_scores_gemma":[0.9826742,0.01163754,0.002980839,0.000449236,0.0006447185,0.001613408],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4155636,0.006112983,0.3156712,0.0001251674,0.003805812,0.004647398,0.00171608,0.00004019644,0.008063934,0.0000834052,0.07731989,0.1668503],"study_design_scores_gemma":[0.1771046,0.04226977,0.7596636,0.0005581698,0.004164756,0.0006625016,0.001014397,0.0001182984,0.002600876,0.0005256223,0.01026398,0.00105339],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9517917,0.01856663,0.00002369134,0.0237505,0.003150884,0.00123134,0.0006531342,0.00005463468,0.0007774568],"genre_scores_gemma":[0.9307961,0.06008434,0.001729219,0.005581323,0.0008333225,0.00005735924,0.00004653713,0.00009557536,0.0007762267],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4439924,"threshold_uncertainty_score":0.9999999,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04116585421662357,"score_gpt":0.4040302561459826,"score_spread":0.3628644019293591,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}